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Abstract
Background: Evidence on the effectiveness of printed educational messages in contributing to increasing
evidence-based clinical practice is contradictory. Nonetheless, these messages flood physician offices, in an attempt
to promote treatments that can reduce costs while improving patient outcomes.
This study evaluated the ability of printed educational messages to promote the choice of thiazides as the first-line
treatment for individuals newly diagnosed with hypertension, a practice supported by good evidence and included
in guidelines, and one which could reduce costs to the health care system.
Methods: The study uses a pragmatic, cluster randomized controlled trial (randomized by physician practice
group).
Setting: The setting involves all Ontario general/family practice physicians.
Messages advising the use of thiazides as the first-line treatment of hypertension were mailed to each physician in
conjunction with a widely read professional newsletter. Physicians were randomized to receive differing versions of
printed educational messages: an “insert” (two-page evidence-based article) and/or one of two different versions of
an “outsert” (short, directive message stapled to the outside of the newsletter). One outsert was developed without
an explicit theory and one with messages developed targeting factors from the theory of planned behaviour or
neither (newsletter only, with no mention of thiazides).
The percentage of patients aged over 65 and newly diagnosed with hypertension who were prescribed a thiazide
as the sole initial prescription medication. The effect of the intervention was estimated using a logistic regression
model estimated using generalized estimating equation methods to account for the clustering of patients within
physician practices.
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Results: Four thousand five hundred four physicians (with 23,508 patients) were randomized, providing 97 %
power to detect a 5 % absolute increase in prescription of thiazides. No intervention effect was detected. Thiazides
were prescribed to 27.6 % of the patients who saw control physicians, 27.4 % for the insert, 26.8 % for the outsert
and 28.3 % of the patients who saw insert + outsert physicians, p = 0.54.
Conclusions: The study conclusively failed to demonstrate any impact of the printed educational messages on
increasing prescribing of thiazide diuretics for first-line management of hypertension.
Trial registration: ISRCTN72772651
Background
The cost-effectiveness of treatment options, particularly
for the treatment of common health conditions, can
have a large impact on the cost of health care. At the
time of the conduct of the present trial, over a third of
Canadians between the ages of 18 and 74 years had
hypertension [1]; and despite the fact that only a fraction
of these individuals were being treated [2], prescription
drugs used in the treatment of hypertension are the
leading therapeutic category of prescription drugs in
Canada, accounting for 20 % of total prescription drug
sales [3]. Decisions concerning the medical management
of hypertension therefore have the potential to have a
significant impact on health care costs.
Initial treatment of hypertension with thiazide diuretics
has been shown to significantly reduce morbidity and
mortality, with benefits at least as great as with other clas-
ses of antihypertensive drugs, at less cost [4]. Yet in
Canada and elsewhere, there is evidence of low adherence
to published recommendations that thiazides be used as
the first-line treatment for patients with uncomplicated
hypertension [2]. The cost to patients and insurers may be
high: one study estimated savings of $13.8 million (in US
dollars in the year 2000) for Canada (year 2000 population
31,281,100) by using thiazides as the first-line antihyper-
tensive drug [2]. Since most individuals with hypertension
were not being treated [2, 5], more aggressive screening
and treatment of hypertension would markedly increase
the number of prescriptions and thus the beneficial eco-
nomic impact of choosing thiazides over other antihyper-
tensive treatment.
Printed educational messages (PEMs) directed to phy-
sicians are one way to address health care gaps that are
under physician influence. While PEMs have the advan-
tages of low cost and easy dissemination, there is great
uncertainty about their effects. Several early systematic
reviews concluded that printed materials, on their own,
do not lead to change in physician practices [6, 7]. How-
ever, Grimshaw observed that the median effect in the
RCTs where guidelines were disseminated as PEMs was
8.1 % absolute risk reduction (range +3.6 to +17.0 %)
[8], on par with other much more expensive interven-
tions like audit and feedback or academic outreach, and
this result was the main stimulus for the current trial. A
subsequent larger review of PEMs observed a smaller
effect size, showing a median absolute risk difference of
0.02 (range 0 to 0.11) in seven RCTs reporting categor-
ical outcomes and a standardized mean difference of
0.13 (range −0.16 to 0.36) in three RCTs reporting con-
tinuous outcomes [9]. A recent review of trials of PEMs
for improving physician behaviour specifically in primary
care settings did not show significant improvement in
physician behaviour across included trials [10].
The uncertainty in the evidence leaves policy makers
uncertain about the role of PEMs, at a time when clos-
ing evidence-to-practice gaps has become a more cost-
effective investment of health system resources than
developing new interventions [11].
Reviews cannot overcome limitations of the primary
evidence: the small number of trials (of varying size) and
methodological weaknesses (insufficient power to detect
modest effects, unit of analysis errors). Thus, there is a
need for a pragmatic [12], randomized controlled trial
on the effect of PEMs on guideline adherence, con-
ducted in real-world settings, on typical practitioners,
taking into account group practices. Given the simplicity
and low cost of PEM-based practice change programs,
and the large population impact that even modest
improvements may achieve when applied to all potential
beneficiaries, a large trial is needed.
We developed and used four criteria to identify im-
portant evidence/practice gaps in Ontario primary care
on which to test the impact of PEMs in a pragmatic trial:
the gap is large and important to patients; it involves a
common disorder; evidence-based practice is not con-
strained by structural or financial barriers; and process
indicators exist that are measurable using the adminis-
trative datasets available to us.
The present study addresses these criteria by targeting
first-line treatment of uncomplicated hypertension using
a thiazide diuretic. This clearly qualifies as an important
primary care gap involving a common disorder not con-
strained by structural or financial barriers and for which
routinely collected administrative data could be used to
evaluate an intervention. If the above-mentioned modest
impact on clinical practice of PEMs is applied, then at
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the trivial cost of a letter to each physician, Ontario’s
health care system stands to save over $1 million, at
current levels of treatment of hypertension [2, 5], with
correspondingly greater savings if identification and
treatment of hypertension is improved. The Ontario
Printed Educational Materials (OPEM) trial aimed to
evaluate different forms of PEMs: long inserts compared
to shorter bullet-pointed outserts and different forms of
outserts. We hypothesized that active arms would be
superior to control, that individually, different forms of
PEMs would be similarly effective on prescribing thia-
zides, and would be more effective when combined and
when developed using a theory of behaviour.
Methods
The interventions
informed was a free, peer-reviewed, evidence-based prac-
tice synopsis, mailed to nearly 15,000 primary care pro-
viders in Ontario from 1994 to January 2007 (when
publication ceased). Articles were developed by clinical
and research staff from the Institute for Clinical Evalu-
ative Sciences (ICES).
Two types of PEMs addressed the identified evidence-
practice gap: a two-page article, indistinguishable from
the rest of the newsletter in size and style (the “insert”)
and two versions of a short, directive, evidence-based
PEM on a postcard-sized card stapled to the front page
of informed (the “outsert”). The insert and one of the
versions of the outsert (the atheoretical outsert) were de-
veloped without any explicit theory of action using input
from a diverse group of physicians who identified bar-
riers to evidence-based practice and from a communica-
tions expert. The second outsert (the theory of planned
behaviour-based outsert) was developed by a group
consisting of three health psychologists and two imple-
mentation researchers with experience using theories of
behaviour. Full details about the development process
for this outsert are described in the study protocol [13].
The addition of the “theory of planned behaviour-based”
outsert allowed us to test the hypothesis that a message
inspired by a psychological theory, specifically the theory
of planned behaviour [14] (TPB), would be more effect-
ive in changing clinical behaviour toward more
evidence-based practice than a message designed with-
out an explicit theoretical basis. The study design is
shown in Table 1. Table 2 shows the two versions of the
outserts, and the insert is included in Additional file 1.
The interventions were included with the July 2005 edi-
tion of informed.
Data sources
Ontario has a single-payer public health insurance
system, in which necessary medical and hospital care
and prescription drugs are covered for all Ontario
residents aged 65 years and older. The following ad-
ministrative data sources from this insurance plan
were used [15, 16]:
 The OHIP Claim History Database details payments
to health care professionals, including an encoded
provider number unique to each health care
professional, an anonymous, encoded patient
identifier unique to each patient, the service
provided and the service date.
 The Canadian Institute for Health Information
(CIHI) Discharge Abstract Database (DAD) contains
the primary and up to 24 secondary diagnoses for all
discharges from acute care hospitals.
Table 1 Study design and number of practice groups/number of physicians
Randomized Included in the analysis
(started at least one patient with uncomplicated
hypertension on medication during the follow-up year)
Intervention Number of practice groups Number of physicians Number of practice groups Number of physicians
1. informed only (no PEM) 1057 1330 947 1166
2. informed plus insert 1058 1265 926 1093
3. informed plus outsert
a. Atheoretical outsert 529 644 475 565
b. TPB-based outsert 529 652 476 585
4. informed plus insert and outsert
a. Atheoretical outsert 529 648 461 550
b. TPB-based outsert 529 640 449 545
Total 4231 5179 3734 4504
Physician practices were randomly assigned to one of four intervention groups. The two intervention groups selected to receive an outsert were further randomly
divided into two sub-groups, one of which received the outsert developed by the OPEM team (atheoretical outsert), the other receiving the TPB-based outsert.
Interventions were included in the July 2005 edition of informed
PEM printed educational message, TPB theory of planned behaviour
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 The OHIP Registered Persons Database (RPDB)
contains basic demographic, place of residence and
vital status information for each insured person.
 The OHIP Corporate Provider Database contains
demographic and practice information for each
physician.
 The Ontario Drug Benefit (ODB) Program database
contains prescription drug claims data for eligible
beneficiaries (age over 65, patients on social
assistance and qualifying for Trillium [low income]
drug program) of the program, including an
encoded prescriber identifier.
Records from these datasets were linked, using unique,
encoded patient and physician identifiers and analysed
at the Institute for Clinical Evaluative Sciences (ICES;
www.ices.on.ca), to determine which individuals were
newly treated for hypertension during the study period,
and which of the target physicians prescribed their anti-
hypertensive medication.
Study practices
All Ontario physicians with an active general/family
practice in Ontario in 2003/2004 were eligible for inclu-
sion. “Active” practice was defined as having a total bill-
ing volume for the year of at least $50,000 and writing
prescriptions for at least 100 different patients (aged
65 years and older), with at least one prescription in at
least 10 of the 12 months.
Physician identifiers were linked to the College of Phy-
sicians and Surgeons of Ontario (CPSO) number at
ICES. CPSO numbers were then hand-linked to the pub-
licly available CPSO database (www.cpso.on.ca) to obtain
practice addresses.
Trials of interventions aimed at changing clinical prac-
tice must be randomized at the level at which they are
directed—in this case, the family physician. In a group
practice, doctors may share information. To prevent
contamination, we randomized at the level of the prac-
tice. Physicians were placed into practices on the basis
of a shared address.
Study patients
The Ontario Drug Benefit database was used to identify
Ontario residents who filled one or more prescriptions
for an antihypertensive medication between July 11,
2005, and July 24, 2006. To ensure that these individuals
were started on an antihypertensive agent for treatment
of hypertension and not another indication, the cohort
was linked with the CIHI DAD, the RPDB and the ODB
Database. We excluded those patients with OHIP claims
within 3 years or CIHI claims within 4 years (or any an-
tihypertensive medications prescribed within 1 year) for
any of the following conditions: myocardial infarction or
angina, heart failure, arrhythmias, renal disease (includ-
ing nephropathy), liver disease (including oesophageal
varices), stroke or transient ischemic attack, hyperthy-
roidism or migraines [17]. Consistent with guideline
Table 2 Theory of planned behaviour and atheoretical outserts
Content of atheoretical message Content of theory of planned behaviour-based message
Message wording Take a new look at THIAZIDES for first-line
treatment for hypertension
Prescribe thiazide diuretics as the first drug to treat patients with
hypertension
✓ BP control equal to all other
antihypertensives
✓ You will be more effective in lowering your patients’ heart
failure risk than if you prescribe calcium channel blockers
✓ Better stroke prevention than ACE
inhibitors
✓ You will be more effective in lowering patients’ stroke risk than
if you prescribe ACE inhibitors
✓ Better heart failure prevention than
calcium channel blockers
✓ You can feel good about giving your patients the most
effective treatment
✓ You will be prescribing one of the most effective drugs as
recommended by the Canadian Hypertension Education Program
Make THIAZIDES the first-line choice for
YOUR patients
Will YOU routinely prescribe thiazide diuretics? YES no
Attributes specified in study protocol
Banner Take a new look at THIAZIDES for first-line
treatment for hypertension (11 words)
Prescribe thiazide diuretics as the first drug to treat patients with
hypertension (12 words)
Up to four bullet points ✓ (3 bullet points) ✓ (4 bullet points)
Up to 85 words ✓ (40 words) ✓ (85 words)
Key clinical messages with footnotes
on back of card
✓ ✓
Cite the ALLHAT trial as evidence
base for the recommended
behaviour
✓ ✓
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recommendations for treatment of hypertension [18], we
focused on thiazide prescribing as the first-line treat-
ment in individuals with uncomplicated hypertension. In
order to ensure that the cohort included only individuals
newly treated for hypertension, individuals who had
filled a prescription for any antihypertensive medication
in the year prior to the intervention were also excluded
[17]. Only the first prescription for an antihypertensive
filled during the observation year was included; all pre-
scriptions filled on the same day were taken into consid-
eration when determining the outcome. While data were
available for individuals 65 years and over, all individuals
included in the study were at least 66 years old at the
time they filled their first prescription for an antihyper-
tensive medication in order to ensure that information
covering a 1-year look back period for prior prescrip-
tions was available.
Using the OHIP physician claims database, we identi-
fied the physician seen during the 14 days prior to and
including the date the antihypertensive prescription was
filled. In some cases, more than one study physician was
selected. (Patients who had not visited any of the study
physicians during the 14-day period were not included
in the analysis.) We included patient visits to the physi-
cian’s office, physician visits to the patient’s home or to a
patient in a long-term care facility and physician phone
calls to the patient.
Study design
The study was a pragmatic, factorial, cluster-randomized
controlled trial with the physician practice as the unit of
randomization. Practices were randomly assigned to one
of six intervention groups by the study statistician (see
Table 1), using computer-generated random numbers. Pa-
tient and physician participants were unaware of allocation
and administrative data were collected without knowledge
of the research under way. Full details of the study design
can be seen in the published protocols [13, 19, 20].
Outcomes
The objectives of the study were to determine whether
the format of the PEM affected the likelihood that the
only medication initially prescribed for hypertension was
a thiazide and whether a theory of planned behaviour-
based approach to developing the message was any more
effective than a PEM developed without use of explicit
theory. A “successful” outcome was a first-line prescrip-
tion for a thiazide and no other antihypertensive medica-
tion. Combinations of a thiazide plus potassium or a
potassium-sparing medication were counted as a “suc-
cess”; combinations of a thiazide plus another diuretic
were counted as a “failure”. A prescription for any non-
thiazide antihypertensive medication was also counted
as a “failure”.
Power
Even a 5 % improvement in the prevalence of care for
common conditions represents a meaningful health
benefit. Based on pilot data, Monte Carlo simulations,
assuming an intracluster correlation coefficient of 0.092,
three patients per physician, a baseline success rate of
0.36 and absolute intervention effects of 0.05, 0.075 and
0.10, demonstrated that a trial with 1250 practices per
arm would provide over 97 % power to detect a 5 %
increase, and over 98 % power to distinguish between
the effects of the combined intervention and either
alone, assuming the combined effect to be additive. This
original power calculation was based on testing the
effectiveness of the insert and one version of the outsert.
We conducted a follow-up simulation to assess whether
we could test a second version of the outsert (theory of
planned behaviour-based), which suggested that the
power would be greater than 80 %. The research oppor-
tunity that this modification presented was judged to
outweigh the loss of power. These decisions were made
during the design phase and prior to randomization, as
detailed in our published protocols [13, 19, 20].
Statistical analysis
Logistic regression was used to test the hypothesis that
the intervention affected the choice of first-line medica-
tion for hypertension. While the unit of randomization
was the physician practice, outcomes were measured at
the individual patient level. The logistic regression
model was estimated using generalized estimating equa-
tions (GEE) to account for the clustering of patients
within physician practices [21]. This method of analysis
allows for the inclusion of patient-level and physician-
level covariates (e.g. patient age, physician age), while at
the same time accounting for possible correlations
amongst patient outcomes within a practice.
Analysis was on an intention-to-treat basis. As shown in
Table 3, models were fit to test: insert and both outserts
combined, and insert and two outserts split (theory of
planned behaviour-based vs. atheoretical). These were fit
using unadjusted (regressions 1a and 2a) models and
models adjusting for patient- and physician-level covari-
ates (regressions 1b and 2b). The full model in 1b included
interaction terms between the intervention and each co-
variate, to determine whether the impact of the interven-
tion depended on patient and/or physician characteristics.
Patient and physician characteristics were compared
between randomization arms using chi-square tests for
categorical variables and Kruskal-Wallis tests for con-
tinuous variables.
All analyses were performed at ICES using SAS ver-
sion 9 (SAS Institute, Cary, North Carolina). Two-tailed
p values less than or equal to 0.05 were considered to
be significant.
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Table 3 Results of the logistic regression
Regression model 1a: unadjusted effect of interventions, insert and combined outserts
Intervention Odds ratio 95 % confidence interval p value
informed only (reference group) 1.00 0.54
+ insert 0.97 0.86 to 1.09
+ outsert 0.93 0.83 to 1.05
+ insert and outsert 1.01 0.90 to 1.14
Regression model 1b: effect of interventions, adjusted for patient and physician
covariates, insert and combined outsertsa
Intervention Odds ratio 95 % confidence interval p value
informed only (reference group) 1.00 0.60
+ insert 0.98 0.87 to 1.11
+ outsert (combined) 0.93 0.83 to 1.05
+ insert and outsert 1.00 0.89 to 1.12
Effect of patient and physician characteristicsb
Physician characteristics
Female (reference is male) 1.27 1.14 to 1.40 <0.0001
Place of training <0.0001
Canada (reference) 1.00
USA 0.90 0.77 to 1.06 0.21
UK, Ireland, Australia, New Zealand 0.75 0.43 to 1.30 0.30
Other 0.53 0.46 to 0.61 <0.0001
Group practice (reference is solo practice) 1.21 1.10 to 1.32 <0.0001
Rural (reference is non-rural) 1.39 1.23 to 1.57 <0.0001
Years since graduation (odds ratio per additional 10 years) 1.06 1.01 to 1.11 0.014
Elapsed time between mail-out and patient visit (odds ratio per additional 30 days) 0.98 0.97 to 0.99 <0.0001
Patient characteristics
Female sex (reference is male) 1.37 1.29 to 1.45 <0.0001
Age (odds ratio per additional 10 years of age) 1.09 1.05 to 1.14 <0.0001
Location of the visit <0.0001
Physician office (reference) 1.00
Long-term care 0.68 0.56 to 0.84 0.0002
Patient’s home 0.96 0.68 to 1.35 0.81
Phone call 0.30 0.13 to 0.70 0.0050
Regression model 2a: unadjusted effect of interventions, with outserts split by type
Intervention Odds ratio 95 % confidence interval p value
informed only (reference group) 1.00 0.69
+ insert 0.97 0.86 to 1.09
+ atheoretical outsert 0.95 0.82 to 1.09
+ TPB-based outsert 0.92 0.80 to 1.06
+ insert and atheoretical outsert 0.97 0.84 to 1.12
+ insert and TPB-based outsert 1.05 0.91 to 1.21
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Results
Physician and patient selection
Figure 1 shows the number of physicians and patients
included in the study. Three quarters of Ontarians aged
66 years and older filled a prescription for an antihyper-
tensive medication in the year following the mail-out,
but almost all (92 %) had already filled a prescription for
an antihypertensive medication during the preceding
year. A further 38 % of those who filled a prescription
for the first time were excluded because there was evi-
dence that the antihypertensive might have been pre-
scribed for a reason other than hypertension. We
identified 38,102 individuals who were taking medication
for hypertension for the first time and were able to link
the prescriptions of 23,508 of these individuals to one of
the physicians targeted by the intervention (Fig. 1). Thir-
teen percent of family physicians randomized to receive
one of the interventions were excluded from the analysis
because they were not linked to at least one patient
newly treated for hypertension.
Physician and patient characteristics
There were small, statistically significant but clinically
unimportant, differences between the characteristics of
the physicians in the six intervention groups (Table 4).
Analysis of intervention effects
The intracluster correlation coefficient was 0.18 (95 %
confidence interval 0.16 to 0.19). Intervention effects are
shown in Table 3. Neither the unadjusted nor the
adjusted results show evidence that any of the interven-
tions, alone or in combination, were effective. The wid-
est confidence interval reported in the table, an odds
ratio between 0.91 and 1.21 for the insert + TPB-based
outsert corresponds to a true absolute effect of the inter-
vention lying between a decrease of 1.5 % and an
increase of 3.5 %. Thus, not only did the intervention fail
to achieve statistical significance but as well the confi-
dence interval does not contain values of much practical
importance.
While the probability of being prescribed a thiazide as
the first-line drug depended on both physician and
patient characteristics, there was no indication that the
interventions themselves were any more or less effective
in any physician or patient sub-group. The p values for
the interactions between the intervention and the phys-
ician/patient variables were all non-significant, ranging
from 0.15 to 0.97.
Discussion
This printed information intervention was designed to
increase physician prescribing of thiazides as the first-
line pharmaceutical treatment for hypertension. The in-
terventions, evaluated in a very large trial, with sufficient
power to detect a small change in physician behaviour,
failed to change prescribing practice. This confirms the
results of studies [22] that found no impact of mailing
Table 3 Results of the logistic regression (Continued)
Regression model 2b: effect of interventions, adjusted for patient and physician
covariates, insert and outserts split by type
Intervention Odds ratio 95 % confidence interval p value
informed only (reference group) 1.00 0.71
+ insert 0.98 0.87 to 1.11
+ atheoretical outsert 0.94 0.81 to 1.08
+ TPB-based outsert 0.93 0.81 to 1.07
+ insert and atheoretical outsert 0.96 0.83 to 1.10
+ insert and TPB-based outsert 1.05 0.91 to 1.21
aThe model was adjusted for these patient variables: age, sex and location of the visit with the physician. The model was adjusted for these physician variables:
year of graduation, sex, place of training, type of practice (solo/group), place of practice (rural/urban) and elapsed time between the mail-out and the office visit
bOdds ratios are adjusted for all of the other variables in the model
p values for interactions with the intervention
Informed subscriber p = 0.73
Rural location p = 0.97
Practice type, p = 0.88
Patient sex, p = 0.81
Location of visit, p = 0.76
Patient age, p = 0.58
GP sex, p = 0.36
Number of years since GP graduation, p = 0.29
Graduation place, p = 0.18
Time from mail-out to patient visit, p = 0.15
p value for four-level intervention = 0.60
p value for six-level intervention = 0.71
All of the main effects are significant
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the Ontario hypertension guidelines to all physicians in
Ontario.
Given the pragmatic and representative nature of our
study, we propose that these results may apply also to
primary care practitioners in other health care settings
with universal health insurance and no cost to patient
for drugs.
This is the first published trial reporting a head-to-
head comparison of TPB-based vs. atheoretical imple-
mentation interventions. Although this trial did not
detect any difference in effectiveness between these two
approaches to intervention, this question needs further
research.
We found that only 27.5 % of the individuals newly
started on antihypertension medication were started
on only a thiazide. This is similar to the rate of 29 %
reported by Morgan et al. [3] for another Canadian
jurisdiction (although Morgan et al. included patients
whose first hypertension treatment was a thiazide
diuretic along with another antihypertensive drug, in
addition to those who received only a thiazide diur-
etic) but lower than the 35 % rate reported for
Ontario between 1994 and 2002 [17].
Female patients and older patients were more likely to
be prescribed thiazides as first-line treatment, corre-
sponding to patterns observed elsewhere [3, 17, 23].
Female physicians, physicians who had been in practice
longer, physicians in group practices and physicians
practicing in rural locations were more likely to pre-
scribe thiazides as first-line treatment (Table 3).
Depending on the condition being treated, improve-
ments in prescribing patterns have the potential to save
patients/insurers money as well as improving patient out-
comes. It is therefore important to pursue other ways of
changing prescribing practices. Several studies report that
a combination of prescribing feedback plus educational
intervention is effective in increasing the rate of thiazide
prescribing [24–26]. The Canadian Hypertension
Fig. 1 Patients and physicians included
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Education Program (CHEP) has been able to produce sus-
tained improvements in the clinical management of
hypertension by combining annual updates of its recom-
mendations with an extensive implementation program
that includes both passive and active dissemination, in-
cluding workshops and academic detailing [27].
An economic analysis found that if the initial improve-
ments in practice can be sustained, they may be cost-
effective [2, 28]. Furthermore, cost-effectiveness of these
interventions should improve as changes in patient
demographics mean that physicians are likely to see
increasing numbers of patients with hypertension in
their practices.
A strength of our study was the use of informed as the
vehicle carrying the PEMs into physician offices. The
effectiveness of printed educational materials depends,
firstly, on whether they are read. In 1997, The Strategic
Council Inc. contacted 500 Ontario physicians by phone
to determine readership and recall of informed. They
found that 71 % of the respondents recalled receiving
informed and that of these, 89 % found it useful or very
useful and 53 % read most or every issue [29]. Two
surveys of informed subscribers, conducted in 1995 and
1999, found that the newsletter was a respected and
valued source of information [29]. It is unlikely, then,
that the failure of this study to change outcomes was
related to the perceived trustworthiness of the source or
the failure of the physicians to notice the messages.
Another strength of the study was the use of adminis-
trative data, which allowed us to examine the impact of
our interventions across the full spectrum of physi-
cians and patients in Ontario. This strength also
imposes some limitations, one of which is the inability
to study non-fee-for-service physicians. However, it is
estimated that only 2 % of Ontario primary care physi-
cians were on alternative payment plans whose billings
did not appear in OHIP claims at the time of the study
[30].
A second limitation imposed by reliance on adminis-
trative data is that we cannot differentiate between fail-
ure of the PEM to be delivered, read or remembered,
failure of the physician to advise the patient and failure
of the patient to act on that advice. While the Canadian
postal service is highly reliable, and the addresses used
are equally so, it is possible that, despite the widely rec-
ognized brand of informed as an evidence-based newslet-
ter from a respected research institute (rather than a
product marketing leaflet), it may not have been received
by study physicians. This is a possible fate for all PEMs
and so does not detract from our main conclusion that
PEMs do not change practice.
From the perspective of patient health, interventions
are useful only if they affect the treatment the patient
receives. This was a pragmatic trial, designed to give a
definitive answer about the value of a particular mode of
information transmission for the purpose of improving
health care. The trial was not designed to explain the
barriers that remained. We did however investigate the
reasons that may explain the lack of observed effect in a
theory-based process evaluation conducted alongside the
trial [31].
Conclusions
Consistent with systematic review findings [9], this study
supports the conclusion that PEMs, whether long and
discursive, or short and directive, and whether based on
a theory of behaviour or no theory at all, did not, on
their own, bring about an effective change in physician
prescribing, even in the absence of financial and struc-
tural barriers to change.
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